8-KCorporate ChangesExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Bylaw Amendment (Feb 22, 2011)

Filed February 22, 2011For Securities:ABT

Summary

This 8-K filing by Abbott Laboratories (ABT) on February 22, 2011, primarily announces a significant change in the company's corporate governance structure. Effective April 29, 2011, the size of Abbott's Board of Directors will be reduced from thirteen members to ten members. This bylaw amendment reflects a strategic decision by the Board to streamline its composition and potentially enhance operational efficiency and decision-making processes. Investors should note this change as it impacts the oversight and governance of the company. While the immediate financial implications are not detailed, a smaller board could signal a shift in strategic focus or a response to evolving governance best practices. The filing also includes the amended and restated by-laws as an exhibit, providing full transparency on the updated governance rules.

Key Highlights

  • 1Abbott Laboratories' Board of Directors size will be reduced from thirteen to ten members.
  • 2This change in the Board size is effective April 29, 2011.
  • 3The amendment to the Board size was approved by Abbott's Board of Directors.
  • 4This is a change to the company's bylaws, specifically Article III, Section 2.
  • 5The amended and restated bylaws, effective April 29, 2011, are filed as an exhibit.
  • 6Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer, signed the filing.

Frequently Asked Questions

The filing states that the Board of Directors amended the bylaws to reduce its size from thirteen to ten members. While specific reasons are not detailed in this 8-K, such changes can be made to streamline governance, improve efficiency, or align with industry best practices.

The reduction in the size of the Board of Directors will be effective April 29, 2011.

This particular filing focuses on a governance change and does not explicitly detail immediate financial implications. However, changes in board structure can sometimes precede or accompany broader strategic shifts that may have future financial impacts.

The amended and restated bylaws of Abbott Laboratories, effective April 29, 2011, are filed as Exhibit 3.1 to this 8-K report.